We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Argenta Announces Integrated Drug Discovery Collaboration with Boehringer Ingelheim
News

Argenta Announces Integrated Drug Discovery Collaboration with Boehringer Ingelheim

Argenta Announces Integrated Drug Discovery Collaboration with Boehringer Ingelheim
News

Argenta Announces Integrated Drug Discovery Collaboration with Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Argenta Announces Integrated Drug Discovery Collaboration with Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Argenta has announced that it has signed a collaboration agreement with Boehringer Ingelheim.

Under the terms of the agreement, Argenta will apply its extensive respiratory drug discovery services to an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio.

Commenting on the agreement, Dr. John Montana, Argenta’s Managing Director said, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading companies in the development of drugs for respiratory diseases, and it is testament to the strength and depth of Argenta’s integrated drug discovery capabilities and expertise in this therapeutic area. We look forward to a fruitful collaboration leading to the delivery of pre-clinical candidates against the target of interest.”

Advertisement